top of page
Newsroom Latest News
Newsroom: In the News
IGX12 Feature in the REPROFACTS 2025 Report
IGX12 featured in the REPROFACTS 2025 report, an independent, curated industry publication highlighting key scientific advances in reproductive medicine and endocrinology.
The report includes expert commentary on Igyxos’ single ascending dose (SAD) study, recognising IGX12 as a first-in-class therapeutic concept in reproductive endocrinology and highlighting its novel mechanism of action, favourable tolerability profile, and long half-life, which may support less frequent dosing in fertility treatment.
bottom of page